Drug development from the bench to the pharmacy: With special reference to dipeptidyl peptidase-4 inhibitor development

Diabetic Medicine

Volumn 33, Issue 6, 2016, Pages 718-722

  Carr, R D ^a  

^a MSD A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1;

DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; ENZYME INHIBITION; HUMAN; PHARMACY; REVIEW; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; FORECASTING; MASS COMMUNICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRENDS;

DIABETES MELLITUS, TYPE 2; DIFFUSION OF INNOVATION; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DISCOVERY; FORECASTING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84968739538     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13066     Document Type: Review

References (32)

1. Jordan VC. Tamoxifen as the first targeted long term adjuvant therapy for breast cancer. Endocr Relat Cancer 2014; 21: R235-R246.
2. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1134.
3. Holst JJ, Ørskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distil gut. FEBS Lett 1987; 211: 169-174.
4. Mosjov S, Weir GC, Habener JF. Insunotropin: glucagon like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-619.
5. Holst JJ. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr Med Chem 1999; 6: 415-431.
6. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
7. Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-1553.
8. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
9. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36 amide), peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835.
10. Kieffer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide. Endocrinology 1995; 136: 3585-3596.
11. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
12. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs. Diabetes 1998; 47: 764-769.
13. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Diabetes 1998; 47: 1253-1258.
14. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54: 2988-2994.
15. Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008; 10: 1057-1061.
16. Rasmussen H, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003; 10: 19-25.
17. Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 2007; 7: 557-568.
18. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875.
19. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13: 7-18.
20. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 2013; 4: 119-145.
21. Lehrke M, Marx N, Patel S, Seck T, Crowe S, Cheng K et al. Safety and tolerability of linagliptin in patients with Type 2 diabetes: a comprehensive pooled analysis of 22 placebo-controlled studies. Clin Ther 2014; 36: 1130-1146.
22. Schweizer A, Dejager S, Foley JE, Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag 2011; 7: 49-57.
23. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes. N Engl J Med 2015; 373: 232-242.
24. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
25. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
26. Montilla S, Marchesini G, Sammarco A, Trotta MP, Siviero PD, Tomino C et al.; AIFA Anti-diabetics Monitoring Group. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metab Cardiovasc Dis 2014; 24: 1346-1353.
27. McKeage K. Trelagliptin: first global approval. Drugs 2015; 75: 1161-1164.
28. Sheu WH, Gantz I, Chen M, Suryawanshi S, Mirza A, Goldstein BJ et al. Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with Type 2 diabetes. Diabetes Care 2015; 38: 2106-2114
29. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 2012; 55: 3262-3272.
30. Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989; 2: 294-306.
31. Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Chung KF, Barnes PJ. Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 1996; 2: 814-817.
32. Alfa RW, Park S, Skelly KR, Poffenberger G, Jain N, Gu X et al. Suppression of insulin production and secretion by a decretin hormone. Cell Metab 2015; 21: 323-333.